By combining JAK2 inhibitors with other targeted therapies, such as inhibitors of BCL-2 (to promote apoptosis) or FLT3 inhibitors (to block additional tyrosine kinase signaling), it is possible to simultaneously target multiple signaling pathways that drive leukemia. The gene discussed is BCL2; the disease is leukemia.